In a report released yesterday, Peter Lawson from Barclays assigned a Buy rating to Tango Therapeutics (TNGX – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $3.44.
Lawson covers the Healthcare sector, focusing on stocks such as ImmunoGen, Replimune Group, and Biomea Fusion. According to TipRanks, Lawson has an average return of 0.8% and a 40.00% success rate on recommended stocks.
Currently, the analyst consensus on Tango Therapeutics is a Strong Buy with an average price target of $17.33.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.56 and a one-year low of $2.47. Currently, Tango Therapeutics has an average volume of 190.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Tango Therapeutics announces first patient dosed in TNG260 Phase 1/2 trial
- Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
- Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
- Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462
